Tesamorelin
Also discussed as: Egrifta
A growth-hormone-releasing hormone analogue with an FDA-approved indication for excess abdominal fat in adults with HIV-associated lipodystrophy. That approval is not a general wellness or anti-aging approval.
Tesamorelin
- Regulatory status
- FDA approved for a specific HIV lipodystrophy indication
- Human evidence
- Approved labeling for one indication only
- Preclinical evidence
- Developing
- Known risks
- See evidence review
- Major unknowns
- Long-term safety
Standardized human dosing
Clinical effectiveness - Last evidence review
- 2026-09-24
- Last regulatory review
- 2026-09-24
A growth-hormone-releasing hormone analogue with an FDA-approved indication for excess abdominal fat in adults with HIV-associated lipodystrophy. That approval is not a general wellness or anti-aging approval.
Why it is trending: public search and clinic marketing have moved faster than a settled human evidence base. This page does not score that attention as benefit or safety.
Human evidence
Human evidence is very limited for a consumer conclusion, except where an approved labeling exists for a specific indication. This review does not invent trial results.
Preclinical evidence
Animal and laboratory papers exist for several of these compounds. Preclinical work does not establish human effectiveness.
Risks and unknowns
Known risks include an incomplete human safety picture and, outside regulated manufacturing, uncertain product identity. Major unknowns include long-term safety, standardized human dosing, and clinical effectiveness.
Reviewed 24 September 2026. Regulatory status can change. Check the FDA record before treating any sentence here as current law.
Related reading
Sources
This page is journalism and research literacy. It is not medical advice and not a product recommendation.